The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 131, No 2, 184-195.
© 2000 American Dental Association

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PADILLA, M.
Right arrow Articles by MERRILL, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PADILLA, M.
Right arrow Articles by MERRILL, R. L.
Related Collections
Right arrow Restoratives

CLINICAL PRACTICE

TOPICAL MEDICATIONS FOR OROFACIAL NEUROPATHIC PAIN: A REVIEW



MARIELA PADILLA, D.D.S., GLENN T. CLARK, D.D.S., M.S. and ROBERT L. MERRILL, D.D.S., M.S.

Background. The authors discuss the local pharmacotherapy for chronic orofacial neuropathic pain disorders such as neuropathies, neuromas and neuralgias.

Methods. The authors conducted a systematic literature review on this topic. The focus of the review involved the two most commonly applied medications for neuropathic disorders—local anesthetics and capsaicin. Other compounds such as nonsteroidal anti-inflammatory drugs, sympathomimetic agents, anticonvulsants and N-methyl-D-aspartate receptor antagonists also were reviewed. The medication delivery and retention methods appropriate for oral and perioral disease and pain control are described in this article.

Results. There are an ever-increasing number of agents that can be used to help patients with neuropathic-based oral and perioral pain problems. Moreover, a clear advancement in the delivery of these medications is the development of a vehicle-carrier agent (pluronic lecithin organogel) that can penetrate the mucosa and cutaneous tissues and carry the active medication with it to the treatment site. The major caveat underlying these treatment strategies is that except for patient testimony and a few studies, there are limited empirical data on the efficacy of most of these new formulations, and additional research is clearly needed.

Conclusions. Because of their rapid onset and low side-effect profile, topical medications offer a distinct advantage over systemic administration for those orofacial disorders that are regional, near the surface and chronic and that demonstrate some response such as pain relief to topical or subcutaneous anesthetics.

Clinical Implications. Practicing dentists now have some new tools they can use to help manage patients who have a chronic nerve pain disorder in and around the mouth.




This article has been cited by other articles:


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
G. H. Pharo and L. Zhou
Controlling Cancer Pain With Pharmacotherapy
J Am Osteopath Assoc, December 1, 2007; 107(suppl_7): ES22 - ES32.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. Sawynok
Topical and Peripherally Acting Analgesics
Pharmacol. Rev., March 1, 2003; 55(1): 1 - 20.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2000 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.